Hastings David C
- SEC CIK
- 0001237401
No open-market purchases or sales filed in the past year.
Current role at each company
- SCYX Scynexis IncDirectoras of Jun 30, 2026
- TRVI Trevi Therapeutics, Inc.Chief Financial Officeras of Jan 12, 2026
- ABUS Arbutus Biopharma CorpChief Financial Officeras of Feb 19, 2025
- ETTX Entasis Therapeutics Holdings Inc.Directoras of Jul 11, 2022
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Hastings David C as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
ABUS Arbutus Biopharma Corp
Chief Financial Officer2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 5, 2025 (view filing) | Feb 4 | 1 day | Hastings David CChief Financial Officer | SSale | −22.2K | $3.28 | −$72.8K | −12.2%159.7K after | 10b5-1 |
| Feb 5, 2024 (view filing) | Feb 2 | 3 days | Hastings David CChief Financial Officer | SSale | −9.59K | $2.31 | −$22.2K | −5.0%181.9K after | 10b5-1 |